SAPROPTERIN DIHYDROCHLORIDE

Search structure


Trade Names:	KUVAN SAPROPTERIN DIHYDROCHLORIDE
Synonyms:	Biopten Dapropterin hydrochloride Kuvan Phenoptin Sapropterin dihydrochloride Sapropterin hydrochloride SUN-0588 SUN-0588 (SHIRATORI) T-1401 T1401 T1401 (BIOMARIN)
Status:	Approved (2007)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	RG277LF5B3
Parent Compound:	SAPROPTERIN

Structure


InChI Key	RKSUYBCOVNCALL-NTVURLEBSA-N
Smile	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1.Cl.Cl
InChI	InChI=1S/C9H15N5O3.2ClH/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7;;/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17);2*1H/t3-,4+,6-;;/m0../s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C9H17Cl2N5O3
Molecular Weight	314.17
AlogP	-1.29
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	6.0
Number of Rotational Bond	2.0
Polar Surface Area	136.55
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	17.0

Pharmacology

Action	Mechanism of Action	Reference
ACTIVATOR	Phenylalanine-4-hydroxylase activator	DailyMed

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Phenylketonurias	4	D010661	ClinicalTrials
Phenylketonurias	4	D010661	ClinicalTrials
Anemia, Sickle Cell	2	D000755	ClinicalTrials
Hypertension	2	D006973	ClinicalTrials
Schizophrenia	2	D012559	ClinicalTrials
Renal Insufficiency, Chronic	2	D051436	ClinicalTrials
Coronary Disease	2	D003327	ClinicalTrials
Intermittent Claudication	2	D007383	ClinicalTrials
Psychotic Disorders	1	D011618	ClinicalTrials
Hypertension, Pulmonary	1	D006976	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Gastrointestinal disorders	16.88
General disorders and administration site conditions	14.05
Psychiatric disorders	11.12
Nervous system disorders	10.96
Respiratory, thoracic and mediastinal disorders	7.22
Injury, poisoning and procedural complications	6.21
Pregnancy, puerperium and perinatal conditions	4.93
Infections and infestations	4.72
Skin and subcutaneous tissue disorders	3.51
Investigations	3.02
Vascular disorders	3.02
Musculoskeletal and connective tissue disorders	2.8
Cardiac disorders	2.33

Cross References

Resources	Reference
ChEBI	32120
ChEMBL	CHEMBL1201775
EPA CompTox	DTXSID0040620
FDA SRS	RG277LF5B3
KEGG	C00272
PDB	H4B
PubChem	135409471
SureChEMBL	SCHEMBL258963
ZINC	ZINC13585233

CONTENTS